The first drug used as BRAF inhibitor in patients with BRAF V600E advanced or metastatic melanoma was sorafenib (BAY 43-9006), which showed promising results in murine models but failed the human experimentation (Eisen et al., 2006; Hauschild et al., 2009). The gene discussed is BRAF; the disease is metastatic melanoma.